77 completed, 20 terminated, 5 withdrawn, 4 unknown. 59 Phase 2, 42 Phase 1, 9 Phase 3, 2 Not applicable, 1 Phase 4.
Follow vandetanib: new trials by email Literature Review of vandetanib trials Research Report on vandetanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Withdrawn | Hoffmann-La Roche | 2023-11-30 | 2024-01-05 | |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma | Phase 2 | Recruiting | West China Hospital | 75 | 2021-06-01 | 2024-12-05 |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Selpercatinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 291 | 2020-02-11 | 2026-03-19 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2018-08-06 | 2021-07-14 |
| Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy CancerSCAN™, Ifosfamide, Carboplatin - Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor | Phase 2 | Unknown | Samsung Medical Center | 90 | 2015-12-01 | 2020-03-19 |
| Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma Vandetanib, Metformin, Vandetanib/Metformin - Renal Cell Carcinoma, Hereditary Leiomyomatosis | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2015-08-26 | 2021-01-26 |
| Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer Fulvestrant, Vandetanib - Neoplasms | Phase 2 | Unknown | Velindre NHS Trust | 160 | 2015-04-01 | 2015-08-21 |
| Vandetanib in Advanced NSCLC With RET Rearrangement Vandetanib - Non Small Cell Lung Cancer | Phase 2 | Completed | Samsung Medical Center | 17 | 2014-11-03 | 2020-12-07 |
| HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) Sunitinib, vandetanib, Erlotinib - Cancer, High-grade Glioma | Not applicable | Unknown | Amsterdam UMC, location VUmc | 15 | 2014-11-01 | 2020-10-08 |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Vandetanib, 131I-mIBG - Phaeochromocytoma, Paraganglioma | Phase 1 | Withdrawn | University College, London | 2014-10-01 | 2015-12-21 | |
| N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy EMA-approved ATI based targeted therapy - Metastatic Cancer | Phase 2 | Completed | Oslo University Hospital | 50 | 2014-05-01 | 2019-03-13 |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients AZD2014, AZD4547, AZD5363 - Non-small Cell Lung Cancer Metastatic | Phase 2 | Completed | UNICANCER | 999 | 2014-04-23 | 2024-01-10 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer AZD2014, AZD4547, AZD5363 - Metastatic Breast Cancer | Phase 2 | Active not recruiting | UNICANCER | 1460 | 2014-04-07 | 2025-01-15 |
| CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice Caprelsa - Metastatic Medullary Thyroid Cancer | Completed | Genzyme, a Sanofi Company | 10 | 2014-04-01 | 2017-05-02 | |
| Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer Vandetanib 300 mg - Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC) | Completed | Genzyme, a Sanofi Company | 31 | 2014-02-17 | 2024-12-18 | |
| Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors Vandetanib - GIST | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2013-12-14 | 2020-03-30 |
| A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study Erlotinib or Gefitinib, Everolimus, Imatinib - Gastrointestinal Cancers | Not applicable | Unknown | Sun Yat-sen University | 50 | 2013-12-01 | 2016-08-30 |
| Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Vandetanib, Placebo - Invasive Breast Cancer | Phase 2 | Terminated | Ronald Weigel | 12 | 2013-10-01 | 2021-11-01 |
| Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Vandetanib (SAR390530), Placebo - Differentiated Thyroid Cancer | Phase 3 | Completed | Genzyme, a Sanofi Company | 238 | 2013-09-17 | 2024-07-23 |
| Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma Vandetanib 300mg - Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma | Phase 1 / Phase 2 | Completed | Genzyme, a Sanofi Company | 14 | 2012-11-01 | 2016-12-05 |
Showing 20 of 109. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (24) · Carcinoma, Medullary (14) · Lung Neoplasms (14) · Neoplasm Metastasis (12) · Neoplasms (10) · Breast Neoplasms (8) · Thyroid Neoplasms (8) · Glioma (6) · Glioblastoma (5) · Prostatic Neoplasms (5) · Brain Neoplasms (4) · Colorectal Neoplasms (4) · Gliosarcoma (4) · Squamous Cell Carcinoma of Head and Neck (4) · Adenocarcinoma (3)
Genzyme, a Sanofi Company (37) · Sanofi (10) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (6) · Dana-Farber Cancer Institute (4) · Annick Desjardins (2) · SWOG Cancer Research Network (2) · Samsung Medical Center (2) · St. Jude Children's Research Hospital (2) · UNICANCER (2) · University of Colorado, Denver (2) · Amsterdam UMC, location VUmc (1) · Barbara Ann Karmanos Cancer Institute (1) · Branimir Sikic (1) · British Columbia Cancer Agency (1)
United States (63) · Spain (16) · France (15) · Italy (15) · United Kingdom (15) · Germany (14) · Canada (12) · Belgium (11) · South Korea (11) · Netherlands (10) · China (9) · Australia (8) · India (8) · Brazil (7) · Sweden (7)
Alberto Broniscer, MD (2) · Brigitte C Widemann, M.D. (2) · W. Marston Linehan, M.D. (2) · Afshin Dowlati, MD (1) · Anne Hansen Ree, Prof. MD PhD (1) · Anne S. Tsao, MD (1) · Annick Desjardins, MD (1) · Annick Desjardins, MD, FRCPC (1) · Branimir I Sikic (1) · Carlos Jimenez, M.D. (1) · Changhu Chen, MD (1) · Christina Thirlwell (1) · Christine H. Chung, M.D. (1)
PMID 25117183, PMID 25881079, PMID 17878480, PMID 20068097, PMID 20570559, PMID 21035955, PMID 21247755, PMID 21282537, PMID 21282542, PMID 22025146, PMID 22586319, PMID 22701615, PMID 22898678, PMID 23442309, PMID 23553066, PMID 23689430, PMID 23766359, PMID 24005613, PMID 24617713, PMID 24709487, PMID 24913066, PMID 25057173, PMID 25503302, PMID 25538178, PMID 25972901, PMID 25982012, PMID 26291023, PMID 26410619, PMID 26715573, PMID 27803005, PMID 29187393, PMID 30297385, PMID 32067679, PMID 32208873, PMID 33075149, PMID 34292174, PMID 35165100, PMID 35943168, PMID 35969032, PMID 37185961, PMID 37870969, PMID 39516358, PMID 39694978, PMID 40304938, PMID 40617171, PMID 40785488
2005 (4), 2008 (1), 2014 (1), 2019 (1), P30CA022453 (1), P30CA043703 (1), U10CA032102 (1)